The ANA immunofluorescence test detects antinuclear antibodies in a patient’s blood by applying serum to cultured cells (HEp‑2) and using fluorescent markers. It screens for autoimmune connective‑tissue diseases—most commonly systemic lupus erythematosus, Sjögren’s syndrome, scleroderma and mixed connective‑tissue disease. Results report titer and staining pattern; a positive test requires clinical correlation and further specific antibody tests for diagnosis.

A fluorescence immunoassay (FIA) is a laboratory test that detects and measures specific antigens or antibodies in blood, urine, saliva, or other samples using fluorescent-labeled antibodies. When the target binds, the fluorescent tag emits light measured by a reader; signal intensity correlates with amount present. FIAs offer high sensitivity and specificity, provide qualitative or quantitative results, and are used for infections, hormones, and biomarkers.

The ANA (antinuclear antibody) test screens for autoantibodies that target components of the cell nucleus, helping detect autoimmune conditions such as systemic lupus erythematosus, Sjögren’s syndrome, scleroderma, and mixed connective tissue disease. IFA (indirect immunofluorescence assay) is the gold‑standard method for ANA testing; it provides antibody titers and fluorescence patterns (homogeneous, speckled, nucleolar, centromere) to guide diagnosis.

ANA results are reported as titres (e.g., 1:40, 1:160). Low titres (1:40–1:80) are common in healthy people; titres ≥1:160 are more suggestive of autoimmune disease. Interpretation depends on clinical context, ANA pattern, and follow-up tests (ENA, anti‑dsDNA). A positive ANA alone does not confirm autoimmunity—diagnosis requires correlation with symptoms and specific autoantibodies.

A positive ANA (antinuclear antibody) isn't automatically alarming. Many healthy people and infections/medications can cause low‑titer positivity. Significance depends on titer, pattern and clinical symptoms. If you have symptoms (joint pain, rashes, fatigue) or high titers, your doctor will pursue further testing for specific autoantibodies and rheumatology assessment. If asymptomatic with low titers, watchful waiting and periodic review is often appropriate.

Positive antinuclear antibodies (ANA) can occur with various malignancies, often as a paraneoplastic phenomenon. Examples include hematologic cancers (lymphoma, leukemia) and several solid tumors such as breast, lung, ovarian, colorectal, gastric and hepatocellular carcinomas. ANA positivity is nonspecific and variable; it may reflect immune dysregulation rather than a diagnostic marker for cancer, so further evaluation is needed.